The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention

Not Applicable

Completed

• Conditions: Peripheral Arterial Disease
• Interventions: Other: Pro-Omega Placebo; Dietary Supplement: Pro-Omega

• Registration Number: NCT02096757
• Lead Sponsor: University of California, San Francisco

Brief Summary

Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral supplementation will improve will improve systemic inflammation and patency of peripheral vascular intervention (PVI).

Detailed Description

The OMEGA-PVI trial is a double-blind, randomized (2:1 active:placebo), placebo-controlled trial with 30 patients aged ≥ 40 years with PAD. Eligible patients will be screened according to specified inclusion and exclusion criteria. All patients will be treated per our current practice as reflected in the American Heart Association Practice guidelines on PAD. n-3 PUFA supplementation will be achieved with 4 capsules of Pro-Omega twice daily (Nordic Naturals, Watsonville, California, USA), corresponding to a total of 4.4g/day given prior to and immediately after the operation. Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. The placebo group will take the same number of capsules containing inactive substance (soybean; Nordic Naturals), designed to be the same color and shape as the treatment capsules. Blood draws, questionnaires, and ultrasounds will be done periodically. Specific measurements will include established markers of inflammation and resolution of inflammation, as well as ultrasound measures of PVI patency. The study proposed here has the potential to provide important new insights on the role of nutritional interventions in PAD, as well as to improve outcomes related to surgical revascularization.

Study Timeline

• Study First Submitted: 2014-03-22
• Study First Submitted QC: 2014-03-22
• Study First Posted: 2014-03-26
• Study Start: 2014-06
• Primary Completion: 2017-03
• Study Completion: 2017-03
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-16
• Last Update Posted: 2020-09-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Disabling claudication or CLI as indication for PVI (Rutherford Class II-V)
• Objective evidence of PAD e.g. ABI < 0.9, TBI < 0.6 or absent pedal pulses
• Currently not taking high-dose n-3 PUFA, as defined by >2 g/day
• Able to provide written informed consent AND
• Undergoing a PVI (catheter-based therapy) involving the aorto-iliac segment, superficial femoral artery or popliteal artery.

Read More

Exclusion Criteria

• Age < 40 or > 90 years
• Undergoing open surgical revascularization
• Evidence of active infection in limb or foot or osteomyelitis
• Extensive tissue loss (Rutherford Class VI Disease)
• Diagnosed hypercoagulable state
• Non-atherosclerotic/aneurysmal disease as indication for procedure
• Chronic liver disease or myopathy
• End-stage renal disease (CKD 5)
• Poorly controlled diabetes (HbA1C > 8%)
• Recent other major surgery or illness within 6 weeks
• Use of immunosuppressives or chronic inflammatory disorders
• History of organ transplantation
• Pregnancy or plans to become pregnant
• Condition in which patient life expectancy is less than one year

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Pro-Omega Placebo	Pro-Omega Placebo soybean capsules; 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
Pro-Omega	Pro-Omega	High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.

Primary Outcome Measures

Name	Time	Method
Systemic Inflammatory bio-markers	6 months	Will reduce circulating pro-inflammatory markers (PIMs) and increase pro-resolution mediators (PRMs) assayed using targeted metabolo-lipidomics, increase PRM production within peripheral circulating monocytes.

Secondary Outcome Measures

Name	Time	Method
Safety	6 months	We hypothesize that n-3 PUFA supplementation in the peri-PVI period will be safe and will not lead to an increase in adverse events including bleeding and pseudoaneurysm formation.

Trial Locations

Locations (1)

San Francisco Veterans Affairs Medical Center; 🇺🇸 San Francisco, California, United States